stoxline Quote Chart Rank Option Currency Glossary
Humacyte, Inc. (HUMA)
2.64  0.11 (4.35%)    12-06 16:00
Open: 2.62
High: 2.695
Volume: 308,727
Pre. Close: 2.53
Low: 2.5
Market Cap: 273(M)
Technical analysis
2023-12-06 4:22:00 PM
Short term     
Mid term     
Targets 6-month :  3.31 1-year :  3.87
Resists First :  2.83 Second :  3.31
Pivot price 2.56
Supports First :  2.29 Second :  1.96
MAs MA(5) :  2.61 MA(20) :  2.49
MA(100) :  2.94 MA(250) :  3.05
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  56.6 D(3) :  64.2
RSI RSI(14): 56
52-week High :  5.59 Low :  1.96
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ HUMA ] has closed below upper band by 25.5%. Bollinger Bands are 66.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.7 - 2.71 2.71 - 2.73
Low: 2.46 - 2.48 2.48 - 2.5
Close: 2.61 - 2.64 2.64 - 2.67
Company Description

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Headline News

Mon, 20 Nov 2023
Humacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent Opportunity (NASDAQ:HUMA) - Seeking Alpha

Tue, 24 Oct 2023
I'm Antsy to Add Tons of Stocks, Including Remitly, ROIV and Beyond Air - RealMoney

Mon, 02 Oct 2023
Several Insiders Invested In Humacyte Flagging Positive News - Yahoo Finance

Fri, 15 Sep 2023
Humacyte enters critical phase for its bioengineered tissue - The Business Journals

Tue, 12 Sep 2023
Humacyte's phase II/III tissue graft data prompt talk of a BLA - BioWorld Online

Tue, 12 Sep 2023
Humacyte's regenerative tissues ace vascular trauma trial - FierceBiotech

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 104 (M)
Shares Float 66 (M)
Held by Insiders 39.7 (%)
Held by Institutions 12 (%)
Shares Short 6,090 (K)
Shares Short P.Month 5,100 (K)
Stock Financials
EPS -0.88
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.36
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -30.5 %
Return on Equity (ttm) -114.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.81
Qtrly Earnings Growth 0 %
Operating Cash Flow -73 (M)
Levered Free Cash Flow -47 (M)
Stock Valuations
PE Ratio -3.04
PEG Ratio 0
Price to Book value 7.33
Price to Sales 0
Price to Cash Flow -3.74
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android